| 000 | 01203 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517200828.0 | ||
| 264 | 0 | _c20181211 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1873-5169 | ||
| 024 | 7 |
_a10.1016/j.peptides.2017.11.023 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMulvihill, Erin E | |
| 245 | 0 | 0 |
_aDipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. _h[electronic resource] |
| 260 |
_bPeptides _c02 2018 |
||
| 300 |
_a158-164 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptidyl Peptidase 4 _xgenetics |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIncretins _xmetabolism |
| 650 | 0 | 4 |
_aLipid Metabolism _xdrug effects |
| 650 | 0 | 4 | _aPostprandial Period |
| 773 | 0 |
_tPeptides _gvol. 100 _gp. 158-164 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.peptides.2017.11.023 _zAvailable from publisher's website |
| 999 |
_c28055978 _d28055978 |
||